EUVIMEDEUVIMED entdecken
Crossref

How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?

Yasmin Isabella El Sammaa-Aru iD, Tanja Schlaikjær Hartwig iD, Maiken Hemme Bro-Jørgensen iD, Emma Juuel Münter iD, Lene Werge, Karina Banasik iD, Finn Stener Jørgensen iD, COPL Consortium, Louise Ambye iD, David Westergaard iD, Henriette Svarre Nielsen iD

Human Reproduction · 24.03.2026

DOI: 10.1093/humrep/deag034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 24.03.2026. Verfasst von Yasmin Isabella El Sammaa-Aru und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Abortion, Spontaneous. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Kirks Foundation, BioInnovation Institute Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY QUESTION How fast does cell-free fetal DNA (cffDNA) decline after early pregnancy loss and which factors affect the decline? SUMMARY ANSWER After pregnancy loss cffDNA declines gradually with detectable levels persisting up to 3 days post-tissue passage correlating with β-hCG decline. WHAT IS KNOWN ALREADY Postpartum clearance of cffDNA occurs within hours, but little is known about its decline following early pregnancy loss. Initial results from the Copenhagen Pregnancy Loss (COPL) study showed slower clearance in relation to pregnancy loss with detectable levels found up to 24 h after tissue passage. STUDY DESIGN, SIZE, DURATION This prospective cohort study included 1463 women from the COPL cohort, enrolled between 12 November 2020 and 19 December 2022. Participants were divided into three groups based on sampling time: the standard group (samples collected before tissue passage), the delayed sample group (samples collected after tissue passage at maximum 24 h), and the repeated sample group (samples collected at multiple time points after medical and surgical treatment). PARTICIPANTS/MATERIALS, SETTING, METHODS Eligible women were 18 years old with a confirmed intrauterine pregnancy loss before 22 gestational weeks. Exclusion criteria included ectopic, molar, or unknown-location pregnancies and inability to consent. For the repeated sample group, additional exclusions were vaginal bleeding at diagnosis, anembryonic pregnancies, and opting for expectant management. Blood samples were analyzed for β-hCG and cffDNA, with fetal fraction measured using the sequencing-based fetal fraction (SeqFF) method. In the repeated sampling group, analyses were performed on Days 2 and 3 for surgically treated and Days 7 and 14 for medically treated. MAIN RESULTS AND THE ROLE OF CHANCE After pregnancy tissue passage, both cffDNA and β-hCG levels declined consistently over time with a corresponding increase in no-call rates. The decline in SeqFF following pregnancy loss occurred more gradually than the immediate clearance previously reported after delivery, remaining measurable for up to 3 days after pregnancy loss, though 30% of samples became inconclusive at this timepoint. The fetal fraction of cffDNA was highest when tissue remained in utero and declined significantly beyond 12-h post-passage (median 4.7% <6 h vs 2.8% >12 h). The no call rate was 9.1% when the tissue was still in situ but increased to 27.1% in the 12- to 24-h post-passage group. Higher β-hCG levels correlated with increased odds of a conclusive cffDNA test (OR 1.30, 95% CI: 1.20–1.43, P < 0.001). β-hCG is accounting for 20% of the variability in fetal fraction measurements. Variability in the decline of cffDNA between groups reflects the differences in the timing of sampling and treatment approaches. LIMITATIONS, REASONS FOR CAUTION The small size of the repeated sample group may limit the generalizability of the findings. Reliance on the SeqFF method introduces variability, as it may not perform consistently. Adjustment for key confounders including BMI, gestational age, type of pregnancy loss, and timing of sampling was performed, but residual confounding cannot be ruled out. WIDER IMPLICATIONS OF THE FINDINGS As a non-invasive method, cffDNA testing offers critical genetic insights for couples facing time-sensitive reproductive decisions or those with recurrent pregnancy loss. The correlation between β-hCG and fetal fraction suggests β-hCG screening could optimize sequencing decisions. These findings support refining cffDNA diagnostics to enhance pregnancy loss evaluation and reproductive care. STUDY FUNDING/COMPETING INTEREST(S) The study was funded by the Ole Kirks Foundation, the BioInnovation Institute Foundation (BII21SG1020554, NNF20SA0066125, and NNF15OC0016662), the Novo Nordisk Foundation (NNF22OC0077221 and NNF23OC0087269), and the A.P. Møller Foundation. The authors have declared their COI. TRIAL REGISTRATION NUMBER N/A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsAbortion, SpontaneousHumansFemalePregnancyProspective StudiesTime FactorsAdultChorionic Gonadotropin, beta Subunit, Human

Stichwörter der Autor:innen

SeqFF methodcell-free fetal DNAclinical managementfetal geneticspregnancy lossβ-hCG

Substanzen

Cell-Free Nucleic AcidsChorionic Gonadotropin, beta Subunit, Human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Hvidovre Hospital's NIPT Center, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

ORCID-Profile: Yasmin Isabella El Sammaa-Aru, Tanja Schlaikjær Hartwig, Maiken Hemme Bro-Jørgensen, Emma Juuel Münter, Karina Banasik, Finn Stener Jørgensen, Louise Ambye, David Westergaard, Henriette Svarre Nielsen

Förderung

  • Kirks Foundation
  • BioInnovation Institute Foundation
  • Novo Nordisk Foundation
  • A.P. Møller Foundation

Zitieren

APA

El Sammaa-Aru, Y. I., Hartwig, T. S., Bro-Jørgensen, M. H., Münter, E. J., Werge, L., Banasik, K., Stener Jørgensen, F., COPL Consortium, Ambye, L., Westergaard, D., & Nielsen, H. S. (2026). How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?. Human Reproduction. https://doi.org/10.1093/humrep/deag034

Vancouver

El Sammaa-Aru YI, Hartwig TS, Bro-Jørgensen MH, Münter EJ, Werge L, Banasik K, et al. How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?. Human Reproduction. 2026. doi:10.1093/humrep/deag034

BibTeX
@article{ElSammaaAru2026,
  author = {El Sammaa-Aru, Yasmin Isabella and Hartwig, Tanja Schlaikjær and Bro-Jørgensen, Maiken Hemme and Münter, Emma Juuel and Werge, Lene and Banasik, Karina and Stener Jørgensen, Finn and COPL Consortium, COPL Consortium and Ambye, Louise and Westergaard, David and Nielsen, Henriette Svarre},
  title = {How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?},
  journal = {Human Reproduction},
  year = {2026},
  doi = {10.1093/humrep/deag034}
}
Kostenlos starten →